Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892666 | 0.89 | FFAR4 (0.45) | FFAR4FFAR1THRATHRBCYP2C9 | |
| SCHEMBL9890648 | 0.81 | HSD17B10 (0.62) | FFAR4FFAR1PTGS1 | |
| SCHEMBL27795110 | 0.79 | GAA (0.50) | FFAR4FFAR1PTGS1 | |
| SCHEMBL1561518 | 0.79 | FFAR4 (0.51) | FFAR4FFAR1CYP2C9PTGDR2 | |
| SCHEMBL9892653 | 0.78 | PSEN1 (0.56) | PTGDR2PTGS1 | |
| SCHEMBL27636056 | 0.78 | IGF2BP2 (0.59) | FFAR4FFAR1CHRM5IGF2BP2GPR3 | |
| SCHEMBL27636104 | 0.77 | PTGDR2 (0.44) | FFAR4PTGDR2PTGS1 | |
| SCHEMBL16429063 | 0.77 | ALOX5 (0.55) | FFAR4FFAR1THRATHRBCHRM5 | |
| SCHEMBL513139 | 0.76 | FFAR4 (0.48) | FFAR4FFAR1CYP2C9SCN5APTGDR2 | |
| SCHEMBL30698114 | 0.76 | FFAR4 (0.48) | FFAR4FFAR1CYP2C9SCN5APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR4 621/4885FFAR1 223/4885THRA 1583/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR4 621/4885FFAR1 223/4885THRA 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.